Page 8 - Fast Track Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Timber Pharmaceuticals (TMBR) Announces FDA Grant of CARC Waiver for TMB-001

Timber Pharmaceuticals (TMBR) Announces FDA Grant of CARC Waiver for TMB-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn koconisTimber pharmaceuticals incDrug administrationWall streetChief executive officerOrphan products grantBreakthrough therapy designationFast track status

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAdam daleyJohn koconisBerry company public relationsTimber pharmaceuticals incCompany annual report on formSecurities exchangeExchange commissionDrug administrationChief executive officerOrphan products grantBreakthrough therapy designationFast track statusTimber pharmaceuticalsSecurities actSecurities exchange act

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCytarabine annaraTacaribe arenavirusWalter klempJenene thomasPrnewswire moleculin biotech incEuropean unionSecurities exchangeCompany core technologiesDrug administrationNational institutes of healthMoleculin biotech incExchange commissionChief executive officerGeneration anthracyclineRecommended phase

Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United statesJenene thomasWalter klempPrnewswire moleculin biotech incExchange commissionDrug administrationMoleculin biotech incSecurities exchangeChief executive officerFast track statusOrphan drug designationMoleculin biotechTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGill shephardWalter klempLiposomal annamycinMoleculin biotech incCompany phaseDrug administrationTeam llcjenene thomasExchange commissionSecurities exchangePrnewswire moleculin biotech incPartial responseFast track statusOrphan drug designationMoleculin biotechTranscription modulator